FAP and sarcoma: Peptide-based FAP-binding radiopharmaceuticals such as FAP-2286 demonstrate sustained retention for up to 10 days with short systemic exposure, translating into favorable clinical responses in both adenocarcinoma and sarcoma cohorts [45,46,61].